Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost ...

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science ...

Patients with nicotinamide exposure don't reveal an increased risk of MACE, suggests a new study published in the ...

NAD infusions are just one of the latest crazes for longevity-seekers, but can it really help you live longer? Here’s what an ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

Nicotinamide use shows no increased cardiovascular risk; prior MACE history remains key predictor of future events.

Many people take dietary supplements like vitamins and minerals to support their health. However, a recent study from the ...

A doctor reported that many studies have found people who are slightly overweight tend to have fewer health problems as they ...

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

ChromaDex Corporation’s CDXC share price has dipped by 10.06%, which has investors questioning if this is right time to buy.

In the pursuit of better health and a longer life, science has uncovered powerful molecules that support cellular function and vitality.